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Summary
There is a need to standardise, within a coordinated Swiss
framework, the practical aspects of genetic testing and
genetic counselling on possibly inherited cardiovascular
disorders in relatives of a sudden cardiac death (SCD)
victim. Because of the major advances in genetic inves-
tigation techniques and recent publication of international
guidelines in the field of cardiology, genetics and patholo-
gy, we consider it important to summarise the current ev-
idence and propose an optimal approach to post-mortem
genetic investigation for SCD victims and their families in
Switzerland. In this article, we discuss important technical,
financial and medico-ethical aspects, and provide updated
information on specific situations in which forensic pathol-
ogists, general practitioners and cardiologists should sus-
pect a genetic origin of the SCD. At present, the principles
of benefit, the duty to warn and the impact of genetic infor-
mation for family members at risk are considered as strong
justifications for post-mortem disclosure and prevail over
the arguments of respect for a deceased person’s priva-
cy and confidentiality. This paper underlines also the need
to update and improve the general knowledge concern-
ing the genetic risk of cardiovascular pathologies, the im-
portance to perform an autopsy and post-mortem genetic
testing in SCD victims, and to develop standardized post-
mortem disclosure policy at national and international lev-
els for SCD cases and relatives.
Keywords: sudden cardiac death, genetic counselling,
autopsy, molecular autopsy
Introduction
Atherosclerotic coronary artery disease (CAD) is recog-
nised as the most common cause of sudden death in the
general population [1]. In a younger population, cardiomy-
opathies and channelopathies are often involved [2, 3]. In
a recent study on sudden cardiac death (SCD) among chil-
dren and young adults 1 to 35 years of age in Australia
and New Zealand, the most common explained causes of
SCD were coronary artery disease and inherited cardiomy-
opathies (24 and 16% of cases, respectively) [4]. Unex-
plained SCD (40% of cases) was the predominant finding
in patients under 31 years of age. The addition of genetic
testing to the autopsy investigation substantially increased
the rate of identification of a possible cause of SCD among
children and young adults, as clinically relevant cardiac
gene mutation(s) were identified in 27% of unexplained
SCD victims. During follow-up, a clinical diagnosis of an
inherited cardiovascular disease was discovered in 13% of
the families [4].
Genetic testing can reveal substrates for not only car-
diomyopathies and channelopathies [5], but also for aortic
diseases and premature atherosclerosis, which may explain
some SCD cases [6, 7]. Aortic aneurisms and dissections,
mainly involving the vasculature of the aortic root and as-
cending aorta, may have a genetic origin, particularly in
young patients, for whom over 15 genes associated with
aortic disease are known today [8–10]. Premature athero-
sclerosis related to familial hypercholesterolaemia should
be suspected in coronary artery disease cases under 55
years in males and under 60 years in females, according to
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the Consensus Statement of the European Atherosclerosis
Society [6]. A possible genetic contribution should also be
considered in SCD cases caused by spontaneous coronary
artery dissection, mitral valve prolapse and pulmonary em-
bolism [11–14].
In Switzerland, the forensic pathologist usually investi-
gates sudden and unexpected deaths of young patients. Our
“Sudden Cardiac Death Working Group” proposed mini-
mum standards for autopsy practice in 2015 [15]; we sug-
gested performing an autopsy in sudden death victims un-
der 40 years of age, collecting and storing post-mortem
frozen material for possible genetic testing for a period of
≥5 years, informing the family about the autopsy results
and providing, when possible, multidisciplinary cardio-
genetic counselling to families of SCD victims [15]. This
document was already in line with the updated recommen-
dations proposed recently by the Association for European
Cardiovascular Pathology (AECVP) [16]. In the current
article, we aim to adapt the guidelines proposed by the
ACEVP in 2017 to the Swiss workflow, and to update the
recommendations we published in 2015, particularly con-
cerning genetic testing and genetic counselling. An inter-
disciplinary collaboration involving general practitioners,
cardiologists, clinical geneticists, psychologist, molecular
biologist and pathologists is proposed, with practical as-
pects in a Swiss framework [17, 18] (fig. 1).
Why to perform an autopsy in SCD cases
With rising opposition towards autopsies in general, a
trend we have noted not only in Switzerland but also in
many other countries, one might argue that a simple blood
sample or minimally invasive techniques might be suffi-
cient to determine the cause of death. Although valuable
information can be obtained with such techniques, they
do not replace an autopsy, which provides superior in-
formation, leading to a better comprehension of the de-
ceased’s pathologies and/or – likewise importantly – lack
of pathologies. A full autopsy is recommended because
minimally invasive autopsies with use of modern imaging
techniques are less accurate than a standard full autopsy,
especially for cardiovascular diseases, and are considered
not sufficient to diagnose the cause of SCD [16, 19]. More-
over, not every genetic anomaly or mutation leads to a
morphological disorder (incomplete penetrance of genetic
disease). Thus, by combining morphological examination
techniques (autopsy and histological examination), toxi-
cology and genetic analyses, one reasonably can include
or exclude different causes of sudden death. This approach
has important implications for the deceased’s family mem-
bers, who might be at risk for similar diseases and eventu-
ally SCD.
Which cases of SCD should be selected for au-
topsy and post-mortem tissue collection?
According to the European and Swiss recommendations
[15, 16], an autopsy should be performed in every SCD
of a young adult. The cut-off age is still a subject of dis-
cussion. After a recent consensus resulting from the work-
shop entitled “Ethical, legal and practical aspects of post-
mortem genetic analysis for sudden cardiac death in young
adults”, organised by the Public and Professional Policy
Committee of the European Society of Human Genetics
Figure 1: Multidisciplinary work around a sudden cardiac death victim.
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and held in Geneva on November 2016, it is recommended
to perform an autopsy in all cases under 40 years of age,
it should be considered in victims between 40 and 65
years of age, and can be decided on case-by-case basis
in individuals older than 65 years of age. Moreover, cases
younger than 40 years who did or did not survive a sudden
cardiac arrest have an indication for genetic testing accord-
ing to the consensus published in 2011 and 2013 [20, 21].
Considering the practical aspects of Swiss forensic prac-
tice, we recommended a general cut off age of 45 years old,
rather than the previous limit of 40 years old. This is a new
proposal and should evidently be applied according to lo-
cal possibilities; an extended age limit could be also be ap-
plied on the basis of the 2017 AECVP recommendations.
Even when coronary artery disease or a specific cardiomy-
opathy is diagnosed in a young case, genetic testing has an
important value for diagnosis, prognosis and treatment of
family members.
In some cases with a cardiovascular morphological sub-
strate identified at the autopsy, there may be an indication
for genetic testing because of the risk that family members
could have the disease (table 1).
The genetic risk should be mentioned in the autopsy report
because of the growing arguments in favour of post-
mortem disclosure to relatives. There is a general need
at national and international levels for a well-considered
post-mortem disclosure policy that offers an optimal bal-
ance between possible benefits and disadvantages. Today,
the principles of benefit, the duty to warn, and the potential
impact of genetic information for family members, are
considered very strong justifications for post-mortem dis-
closure. These arguments prevail over respect for the de-
ceased’s wishes as expressed in life, and the respect for the
deceased’s privacy and confidentiality [22, 23]. In practice,
we propose also a short standard letter, which should be
sent to the district attorney by the forensic pathologist in
order to inform about the storing of post-mortem samples.
Why is it important to recommend multidisci-
plinary genetic counselling/testing to first-de-
gree relatives after a SCD in the family?
Families of a SCD victim find relief when a causal expla-
nation of the event is given [24]. The yield of the genetic
test, however, is at best 30% in sudden unexplained death
syndrome (SUDS) victims [25] and 10% in sudden infant
death syndrome (SIDS) [26, 27]. Since there is a poten-
tial unrecognised genetic disorder in the family, it is de-
sirable to offer cardiogenetic counselling to all first-degree
relatives of a young (<45 years old) SCD/SUDS or SIDS
victim. It should ideally be performed by a multidiscipli-
nary team consisting of a cardiologist, geneticist and psy-
chologist [28], before and after genetic testing [29] (fig. 1).
Genetic counselling does not replace the routine clinical
cardiac evaluation, expected to be performed in all first-de-
gree relatives of a young SCD or SIDS/SUDS victim. The
goal is to offer psychological support, answer all questions
and discuss with the relatives the genetic aspects of SCD
and the potential implication for their own health. The
process of genetic counselling incorporates the interpreta-
tion of family and medical histories in search of potential
genetic causes. During the counselling, instruction about
the inheritance of the suspected genetic disease should be
provided. The relatives should be informed about the ad-
vantages and disadvantages of the genetic test, including
the implications of a positive or a negative test result, mu-
tation detection rate, possibility of unexpected or unclear
genetic findings and costs of the test. The genetic coun-
selling session should be non-directive and help the rela-
tives to make informed choices.
It is mandatory to provide informed consent for a genetic
test, for which minimum content requirements have been
recommended by the Swiss Society of Medical Genetics
and are available online (http://sgmg.ch). The patient and
the treating physician should sign the document.
Table 1: Cardiogenetic studies of family members. Class of recommendations based on autopsy findings of the proband. (Adapted from Basso et al. [16]).
Finding autopsy Age limit* Possible mutated genes Class of recommendation
for referral of first degree
family members for clinical/
genetic counseling†
Level of evidence‡
Unknown/uncertain cause of death ≤40 Mainly ion channel genes I C
Hypertrophic cardiomyopathy No limit Sarcomeric genes and other disease re-
lated genes
I C
Arrhythmogenic cardiomyopathy No limit Desmosomal genes and other disease
related genes
I C
Dilated cardiomyopathy No limit Sarcomeric, cytoskeleton genes and oth-
er disease related genes
I C
Premature atherosclerosis Men <40 Women
<50
Familial hypercholesterolaemia genes IIa C
Thoracic aortic aneurysm / dissection /
rupture with medial degeneration
Unknown Syndromic and non-syndromic aortic
aneurysm related genes
I C
Spontaneous coronary artery dissec-
tion
No limit Connective tissue disease related genes IIa C
Pulmonary embolism Unknown Hereditary thrombophilia genes IIb C
SUDEP Unknown Overlap with ion channels related genes IIa C
SUDEP = sudden unexpected death in epilepsy * Age limit refers to age at autopsy of the deceased case. Comment for Swiss practice: we recommend as general practice a
cut-off age of 45 years. † I: is recommended; IIa: can be useful; IIb: may be considered; III: is not recommended. ‡ A: data derived from multiple randomised clinical trials or
meta-analyses; B: data derived from a single randomised clinical trial or large nonrandomised studies. C: consensus of opinion the experts and/or small studies, retrospective
studies, registries.
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Psychological aspects when dealing with the
family of a SCD victim
After a SCD, relatives display increased anxiety, depres-
sion, stress and posttraumatic symptoms with prolonged
grief [30, 31]. Some relatives also display guilty feelings
or blame others, as it is difficult to make sense of such an
event. Often the possible genetic nature of the disease is re-
vealed while relatives are still mourning. As cognitive ca-
pacities may be impaired, decision-making about genetic
testing may be complicated [32], as relatives also have
to deal with the implications of a potential genetic condi-
tion affecting their own lives [33]. Genetic knowledge may
sometimes be available only months after the death. In this
case, the family interpretation of the death meshes with the
medical explanation, reshaping family dynamics.
Sharing genetic information with relatives is never trivial
and may generate a great deal of anxiety. Disclosing this
information may improve, but also worsen, family com-
munication and dynamics [34]. Predictive testing can af-
fect the psychological well-being of parents for a long peri-
od of time [35]. Fear of developing symptoms, difficulties
in considering prophylaxis (e.g., medical surveillance, beta
blockers, internal cardio-defibrillator, exercise restriction,
etc.), fear of impairing emotional well-being, especially
when it comes to the children, might refrain from genet-
ic testing or communication about it [36]. The inequali-
ties of genetics are also difficult to apprehend (why does
one child carry the mutation and not his siblings, for in-
stance?). Paradoxically, being the only one in the family
not to carry a pathogenic mutation is sometimes difficult,
leading to feelings of exclusion or guilt.
The genetic counselling team should adapt their planed
session to the family profile when choosing the setting of
the meeting (each member separately or all together) [36,
37]. The information should be adapted to the age and ma-
turity of the persons at risk, especially when talking to chil-
dren and teenagers [34], but also to the elderly or the dis-
abled. Underage children should be fully part of the genetic
counselling process if indicated; their own questions and
fears should be addressed.
The presence of a mental health professional in the cardio-
genetic team will allow better detection of psychological
comorbidity, which may also imply better compliance with
and acceptance of medical recommendations [38] (fig. 1).
In which situations is it important to perform a
cardiological clinical evaluation in relatives of
a SCD victim?
All first degree relatives of a young SCD victim should be
referred to the cardiologist for clinical evaluation, which
is usually in the frame of cardiogenetic counselling. The
cardiologist will select the necessary examinations on the
basis of the personal and family history. Basic evaluation
should typically include a resting 12-lead electrocardio-
gram (ECG), echocardiography, 24-hour ECG, a stress test
and if necessary cardiac magnetic resonance imaging
(MRI).
What information can be provided by genetic
testing?
Genetic testing should ideally be first performed on sam-
ples from the SCD victim. The value of the post-mortem
genetic test in a victim of SCD lies in extending genetic
screening to the relatives and eventually allowing detection
of asymptomatic carriers at risk once the causative muta-
tion has been identified. Establishing a clear genetic diag-
nosis in victims of SCD allows the initiation of measures
to prevent SCD, and guidance with respect to reproductive
options in affected families. Implications of a positive ge-
netic test are determined by the association of the iden-
tified mutation with a particular disease, and are sum-
marised in the international expert consensus statements
[39, 40]. Concerning the diagnostic yield of the genetic
test, it should be emphasised that:
– The yield of genetic testing depends on the results of
the forensic autopsy.
– When a particular cardiomyopathy phenotype is recog-
nised at autopsy, the yield of the test is higher.
– It is important to recognise the limitations of the test. If
a genetic cause cannot be determined, it is either be-
cause of limited current knowledge in the field or be-
cause the cause of death was not a genetically deter-
mined disease. Families should be informed about these
issues.
– Genetic testing represents an important tool in the eval-
uation of SCD and is a very useful method to identify
population at risk to develop SCD.
Genetic testing: which genes to include? Role
of new technologies
There are no specific guidelines on the type or extent of the
genetic test to be performed. So far, the number of genes
tested and the technique used are selected by each labora-
tory or suggested by the referral physician. Most of the lab-
oratories nowadays use next-generation sequencing, which
allows multiple genes to be screened at the same time. Al-
though there is no evidence that broader panels offer a sig-
nificantly higher yield in SCD, SUDS or SIDS victims,
there is a general tendency to use them.
The autopsy findings and the clinical history can guide the
test when a specific condition is diagnosed or suspected.
When the death remains unexplained, we recommend per-
forming a genetic examination that includes at least the
major genes implicated in channelopathies and cardiomy-
opathies. These major genes are provided in the guide-
lines for genetic testing [39]. The addition of minor genes,
which usually explain less than 5% of the cases of a partic-
ular disease, may slightly increase the yield of the test.
At a clinical level, only pathogenic or probably pathogenic
variants, as in the guidelines of the American College of
Medical Genetics [41], should be reported. For variants
of uncertain clinical significance (also called VUS), it is
absolutely essential to discuss during the pre-test genetic
counselling whether or not the family members wish to be
informed about such findings if detected.
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How are genetic analyses/counselling for SCD
victims and their relatives paid for in Switzer-
land?
The insurances companies in Switzerland pay for genetic
counselling. However, genetic testing in the deceased is
not covered, neither by any insurance company nor by the
district attorney who orders the forensic autopsy. This rep-
resents a real problem in the diagnostic flow of these cases
since, according to the international recommendations, the
test should be performed first in the deceased person.
For the family members, predictive genetic testing in
Switzerland is not reimbursed, unless there is a clear thera-
peutic implication. Attending physicians should write a re-
quest to the insurance provider justifying the test and even-
tually the insurance will agree to pay.
It is important to recognise that genetic testing has become
cheaper and faster, and covers more genes in one test. It is
cheaper to perform a genetic test in a SCD victim, than reg-
ular medical-cardiovascular check-ups in all first-degree
relatives every 3 to 5 years indefinitely. Genetic testing of
the deceased needs the consent of the next-of-kin. If no ge-
netic material is available from the deceased person, genet-
ic testing can be performed in selected family members.
Genetic counselling/testing in SCD cases over
45 years old
Since in 80% of SCD victims older than 45 years old the
cause of death is coronary artery disease without a substan-
tial genetic contribution, a genetic test usually has less val-
ue as a diagnostic tool in this group [1, 4]. The indication
for the genetic test will depend on family history and the
evidence of disorders having a genetic origin.
Role of general practitioners in SCD coun-
selling
The general practitioner (GP) should recognise a SCD vic-
tim in which the cause is unclear and recommend an autop-
sy, particularly in cases younger than 45 years of age. After
a SCD, family members usually turn to their GP first. Af-
ter the legal section, the GP will receive an autopsy report
of the deceased, which discusses possible genetic causes of
the SCD; alternatively, questions about hereditary causes
of the SCD might come up in the course of the consulta-
tion. Thus, the role of the GP in advising, counselling and
organising is central to assisting affected family members
(see fig. 1).
To help family members to make informed decisions, it is
important to explain the findings of the autopsy and the
often complex state of affairs. Here, as a person of trust,
the GP has the important task of “translating” the autop-
sy report and explaining the implications of the findings to
family members. The right of family members to remain
ignorant should be respected as much as their desire for
clarification.
The GP should send the autopsy report to the genetic coun-
selling team. The autopsy protocol provides indications of
the possibly underlying hereditary disease, as well as a list
of the post-mortem material collected, able to be used for
genetic testing depending on the situation. However, after
the legal section, the permission of the public prosecutor
is needed in order to release the autopsy report or autop-
sy protocol to family members or their physicians. In this
respect, the corresponding Institutes of Forensic Medicine
may provide organisational assistance to the GP.
Conclusions
The procedures following a SCD involve not only forensic
doctors, but also cardiologists, geneticists, general practi-
tioners, pathologists and psychologists, who should pro-
vide a comprehensive optimal “cardiogenetic counselling”.
There is a need to update and improve the general knowl-
edge concerning the genetic risk of cardiovascular patholo-
gies and the importance of an autopsy and genetic testing,
not only among the medical community but also among the
juridical and public health authorities.
Family members of SCD victims younger than 45 years
old with an unclear cause of death or SCD victims with a
clear heritable cause at autopsy at any age, should be di-
rected to a specialised centre for cardiogenetic counselling
and genetic testing.
We understand the difficulties faced by different centres in
Switzerland in implementing these recommendations, and
we invite physicians involved in the management of a SCD
victim or family members to contact our working group if
assistance is needed.
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